Well that is disappointing
“The study did not meet its primary efficacy endpoint of MACE reduction at 90 days. As a result, there are no plans for a near-term regulatory filing. There were no major safety or tolerability concerns with CSL112.”
the leading health company stumbles again.
Well that is disappointing “The study did not meet its primary...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$279.92 |
Change
0.000(0.00%) |
Mkt cap ! $135.2B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20 | $307.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $251.92 | 103 | 4 |
View Market Depth
| Last trade - 09.53am 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$281.30 |
Change
0.000 ( 0.47 %) |
||||
| Open | High | Low | Volume | ||
| $280.00 | $281.55 | $280.00 | 488 | ||
| Last updated 10.14am 14/05/2024 ? | |||||
| CSL (ASX) Chart |